The absence of strong cytotoxicity of FXR agonists like PX20350 or PX20606 and their hepatoprotective activities may also make them possible candidates for a combination with classical chemotherapy or multi-kinase-targeted anti-tumor therapies such as Sorafenib. The gene discussed is NR1H4; the disease is neoplasm.